Indirect Comparisons of Adverse Events and Dropout Rates in Early Parkinson's Disease Trials of Pramipexole, Ropinirole, and Rasagiline

REFERENCES

• Gallagher DA, Schrag A. Impact of newer pharmacological treatments on quality of life in patients with parkinson's disease. CNS Drugs. 2008;22(7):563–86.
   PubMedGoogle Scholar
• Jankovic J. Parkinson's disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–76.
   PubMed Web of Science ®Google Scholar
• Pahwa R, Lyons KE. Early diagnosis of parkinson's disease: Recommendations from diagnostic clinical guidelines. Am J Manag Care. 2010;16(Suppl Implications):S94–9.
   PubMedGoogle Scholar
• Macleod AD, Counsell CE, Ives N, Stowe R. Monoamine oxidase b inhibitors for early parkinson's disease. Cochrane Db Syst Rev. 2005;(3): CD004898.
   Google Scholar
• Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: Initiation of treatment for parkinson's disease: An evidence-based review: Report of the quality standards subcommittee of the american academy of neurology. Neurology. 2002;58(1):11–7.
   PubMed Web of Science ®Google Scholar
• Olanow CW. The role of dopamine agonists in the treatment of early parkinson's disease. Neurology. 2002;58(2):33–41.
   Google Scholar
• Lopez IC, Ruiz PJ, Del Pozo SV, Bernardos VS. Motor complications in parkinson's disease: Ten year follow-up study. Mov Disord. 2010;25(16):2735–9.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Swope DM. Pharmacotherapy for parkinson's disease. Pharmacotherapy. 2007;27(12 Part 2):161S-73S.
   Google Scholar
• Thobois S. Proposed dose equivalence for rapid switch between dopamine receptor agonists in parkinson's disease: A review of the literature. Clin Ther. 2006;28(1):1–12.
   PubMed Web of Science ®Google Scholar
• Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, Shah L, Wheatley K, Gray R. Dopamine agonist therapy in early parkinson's disease. Cochrane Database Syst Rev. 2008(2):CD006564.
   PubMedGoogle Scholar
• Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of parkinson's disease. Clin Ther. 2007;29(9):1825–49.
   Google Scholar
• Chen JJ, Ly A-V. Rasagiline: A second-generation monoamine oxidase type-b inhibitor for the treatment of parkinson's disease. Am J Health Syst Pharm. 2006;63(10):915–28.
   PubMedGoogle Scholar
• Parkinson SG. A controlled, randomized, delayed-start study of rasagiline in early parkinson disease. Arch Neurol. 2004;61(4):561–6.
   PubMedGoogle Scholar
• Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions ver. 5.1.0 [updated march 2011]: The Cochrane Collaboration; 2011. Available from: www.cochrane-handbook.org.
   Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–91.
   PubMed Web of Science ®Google Scholar
• R development core team. R: A language and environment for statistical computing. R foundation for statistical computing, vienna, austria. 2011. Available from: http://www.R-project.org.
   Google Scholar
• Spiegelhalter D, Abrams K, Myles J. Bayesian approaches to clinical trials and health-care evaluation. 1st ed. Chichester: John Wiley & Sons; 2004. Chapter 8, Evidence synthesis; p. 267–99.
   Google Scholar
• Lunn DJ, Thomas A, Best N, Spiegelhalter D. Winbugs –a bayesian modelling framework: Concepts, structure, and extensibility. Stat Comput. 2000;10(4):325–37.
   Web of Science ®Google Scholar
• Parkinson SG. Safety and efficacy of pramipexole in early parkinson disease. A randomized dose-ranging study. Parkinson study group. JAMA. 1997;278(2):125–30.
   PubMedGoogle Scholar
• Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: Report of the ispor task force on indirect treatment comparisons good research practices: Part 2. Value Health. 2011;14:429–37.
   PubMed Web of Science ®Google Scholar
• Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med. 2009;28(14):1861–81.
   PubMed Web of Science ®Google Scholar
• Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of parkinson's disease: Meta-analysis of randomized controlled trials. Drug Saf. 2010;33(2):147–61.
   PubMedGoogle Scholar
• Michinaga S, Hisatsune A, Isohama Y, Katsuki H. An anti-parkinson drug ropinirole depletes orexin from rat hypothalamic slice culture. Neurosci Res. 2010;68(4):315–21.
   PubMed Web of Science ®Google Scholar
• Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with parkinson's disease: A meta-analysis. Drug Safety. 2003;26(6):439–44.
   PubMedGoogle Scholar
• Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J, O'Brien CF. Ropinirole for the treatment of early parkinson's disease. The ropinirole study group. Neurology. 1997;49(2):393–9.
   PubMed Web of Science ®Google Scholar
• Shannon KM, Bennett JP, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate parkinson's disease. The pramipexole study group. Neurology. 1997;49(3):724–8.
   PubMed Web of Science ®Google Scholar
• Goetz CG. [movement disorder society-unified parkinson's disease rating scale (mds-updrs): A new scale for the evaluation of parkinson's disease]. Rev Neurol (Paris). 2010;166(1):1–4.
   PubMed Web of Science ®Google Scholar
• Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology. 1967;17(5):427–42.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172(1):137–59.
   PubMed Web of Science ®Google Scholar
• Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43–6.
   PubMedGoogle Scholar
• Berry DA, Hochberg Y. Bayesian perspectives on multiple comparisons. J Statist Plann Inference. 1999;82(1):215–27.
   Web of Science ®Google Scholar
• Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: Empirical evidence from published meta-analyses. BMJ. 2003;326(7387):472.
   PubMed Web of Science ®Google Scholar
• Ceravolo R, Frosini D, Rossi C, Bonuccelli U. Impulse control disorders in parkinson's disease: Definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord. 2009;15(Suppl 4):S111–5.
   PubMedGoogle Scholar
• Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in parkinson disease: A cross-sectional study of 3090 patients. Arch Neurol. 2010;67(20457959):589–95.
   PubMedGoogle Scholar